Skip to content

Evaluating the effects of magnesium in colistin nephrotoxicity

Evaluating the effect of intravenous magnesium sulphate for prevention of colistin induced Acute Kidney Injury

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130917014693N15
Enrollment
96
Registered
2023-01-12
Start date
2023-01-21
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury. Acute kidney failure, unspecified

Interventions

Intervention 1: Intervention group: Colistin therapy begins with a dose of 9-12 million IU as 1-hr infusion and maintenance therapy continues after 12 hours of the loading dose, with a daily dose of 9

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with indication of colistin therapy patients with GFR> 60ml/min patients with magnesium blood level between 1.9 and 3 mg/dl

Exclusion criteria

Exclusion criteria: patients younger than 18 years patients with GFR< 60ml/min patients with magnesium blood level of less than 1.9 or more than 3 mg/dl Pregnant patients

Design outcomes

Primary

MeasureTime frame
Acute Kidney Injury occurrence. Timepoint: Daily during the first week of colistin therapy. Method of measurement: The Kidney Disease Improving Global Outcomes (KDIGO) criteria for Acute Kidney Injury.

Secondary

MeasureTime frame
Escalation or de-escalation of therapy. Timepoint: Daily during the first week of colistin therapy. Method of measurement: Colistin daily dose observation.;Length of hospitalization. Timepoint: At the time of discharge. Method of measurement: Counting the number of days.;Death. Timepoint: Daily. Method of measurement: Records Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Sahraei

Shahid Beheshti University of Medical Sciences

z.sahraei@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026